SmithKline's Nicoderm CQ will be second transdermal patch on market.

OTC NICODERM CQ WILL BE ON STORE SHELVES BY LABOR DAY following the Aug. 2 FDA approval of the transdermal nicotine replacement therapy, SmithKline Beecham and Hoechst Marion Roussel jointly announced in a same-day release. The companies are touting Nicoderm CQ ("committed quitters") as "the first and only OTC nicotine patch to be available in all prescription strengths: 21 mg, 14 mg and 7 mg per day." The product trails McNeil's transdermal Nicotrol patch to the over-the-counter market by about a month and a half ("The Tan Sheet" July 8, p. 1).